Cullinan Oncology, Inc. (CGEM) Tops Q3 EPS by 43c

Cullinan Oncology, Inc. (NASDAQ: CGEM) reported Q3 EPS of ($0.54), $0.43 better than the analyst estimate of ($0.97). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Cullinan Oncology, Inc. (CGEM) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Morgan Stanley course-corrects their semiconductor equipment outlook on demand
• BofA maintains underperform ratings on six BDC stocks